Subscribe to Newsletter
Discovery & Development Vaccines, Translational Science

Beyond the Storm

Back in 2017, we explored what healthcare and pharma might look like in 100 years’ time (1); the experts I spoke with were intrigued by the premise, but were quick to point out that it’s hard to predict what will happen in five years’ time – and so virtually impossible to imagine a world in 2100 (although they still tried!). As 2020 has proven, even six months can seem like a very long time. The term “COVID-19” didn’t exist in November 2019, but by mid-March it was a household name, with most of us living in lockdown, trying to come to terms with how quickly a black swan event can transform our lives.

Right now, I don’t know what 2021 will look like, but I do know that a single revolutionary medicine or vaccine could significantly transform the COVID-19 outlook. And the whole research and development community is working hard to bring us that breakthrough sooner rather than later.

But what lies beyond COVID-19? There are many diseases that could benefit from all the collaborative effort and funding being poured into COVID-19. What if the world could rally around malaria or tuberculosis in the same way? Vaccines and treatments already exist for TB, but it still killed 1.4 million people in 2019 (2). Experts have also expressed concerns about the pandemic’s impact on the treatment of other infectious diseases (3); once the COVID-19 storm passes, it’s likely we’ll need a thorough reassessment of global healthcare priorities.  

Where else can the wider pharma industry develop partnerships to bring about drastic improvements? Manufacturing seems like one area that could benefit; most vendors work alongside pharma partners, but few vendors work together – or with partners outside the industry – to develop truly revolutionary tools. And yet, working together seems like the fastest way toward disruptive change.

On that note, our cover feature for the November issue looks at one provocative (and, if successful, disruptive) direction: the ability to synthesize biologic medicines in any location – even on Mars. Sound far-fetched? in this issue, scientists explain how it is possible, perhaps offering us a glimpse of what could lie on the post-pandemic horizon.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. The Medicine Maker, “November 2017 Issue of The Medicine Maker” (2017). Available at
  2. WHO, “Tuberculosis” (2020). Available at
  3. Nature, “How to stop COVID-19 fuelling a resurgence of AIDS, malaria and tuberculosis,” (2020). Available at
About the Author
Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine